Imaging the breast following neoadjuvant chemotherapy: does improvement of imaging findings in the axilla predict pathological response in the breast?
© Williams et al.; licensee BioMed Central Ltd. 2012
Published: 9 November 2012
Neoadjuvant chemotherapy is an effective treatment in patients with locally advanced breast cancer. It is being used more frequently and imaging is used to monitor disease response. Imaging response in the axilla was correlated with the final breast histology.
Patients who had undergone primary chemotherapy, pre and post chemotherapy MRI and surgery from 2009 to present were included. The MRI and histology reports were reviewed.
Of 20 patients, 18 had abnormal nodes on the first MRI; of these nine had a complete imaging response and five had axillary disease on final pathology. Of the nine that had abnormal nodes on their final MRI, all but one had metastatic disease on final pathology. Of the nine patients with a response on axillary imaging, two had a complete pathological response in the breast. The other had an average tumour size of 53 mm (range 16 to 120 mm). Of the patients who did not respond radiologically in the axilla, three had a complete pathological response in the breast and the remainder had an average tumour size of 44 mm (range 1.7 to 90 mm).
Although MRI is used to predict response to chemotherapy it may underestimate and overestimate disease burden. A radiological response in the axilla does not predict a response in the breast and the two areas need to be assessed independently of each other. Surgical planning must take into consideration the pre-chemotherapy disease status in each area.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.